Skip to content
Screener

Arrowhead Research ARWR Shares (Diluted)

Shares (Diluted) at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
165.4M-9.3%
ALN
Alnylam PharmaceuticalsALNY
138.3M+5.9%
Assembly Biosciences logo
Assembly BiosciencesASMB
16.9M+125%
Arbutus Biopharma Corporation logo
Arbutus Biopharma CorporationABUS
195.2M+2.4%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
101.9M+3.5%
Beam Therapeutics logo
Beam TherapeuticsBEAM
103.3M+17.4%

Other financials

Income statement

See full
Revenue$73.7M-86.4%
Operating income-$141.3M-137%
Net income-$132.7M-136%
EPS (diluted)-$0.93-134%

Balance sheet

See full
Cash & equivalents$188.5M+1.5%
Total debt$107.9M-5.6%
Total equity$614.0M-10.1%
Total assets$2.3B+44.2%

Cash flow

See full
Operating cash flow$84.4M-81.6%
CapEx$2.6M-51.6%
Free cash flow$81.9M-82.0%

Valuation

See full
Market cap$12.28B+445%
Enterprise value$12.2B+446%
P/S19.7×+15.8×

Profitability

See full
Operating margin-35.7%+63.6pp
Net margin-48.4%+240pp
FCF margin1.8%+0.9pp

Returns & leverage

See full
Return on equity-46.4%+341pp
Debt / equity0.2×0.0×
Current ratio6.2×+1.1×

Where this comes from

Reported directly by Arrowhead Research in its filing.

Tagged under the XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding.

The source filing: Arrowhead Research’s 10-Q, filed May 7, 2026.

Filed
May 7, 2026, 4:05 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q1 2026
Accession
0000879407-26-000047
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025Six Months Ended March 31, 2026Six Months Ended March 31, 2025
Diluted$(0.93)$2.75$(0.73)$1.52
Weighted-average shares used in calculating
Basic142,417133,363139,762129,059
Diluted142,417134,484139,762130,265
Comprehensive (loss) income:
Net (loss) income including noncontrolling interest$(137,572)$367,863$(109,328)$192,645
Other comprehensive (loss) income, net of tax:
Unrealized (losses) gains on available-for-sale securities(6,934)653(6,788)146

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is Arrowhead Research's shares (diluted)?
Arrowhead Research (ARWR) reported shares (diluted) of 142.4M in Q1 2026.
How has Arrowhead Research's shares (diluted) changed year-over-year?
Arrowhead Research's shares (diluted) increased by 5.9% year-over-year, from 134.5M to 142.4M.
What is the long-term trend for Arrowhead Research's shares (diluted)?
Over 4 years (2021 to 2025), Arrowhead Research's shares (diluted) has grown at a 6.4% compound annual growth rate (CAGR), from 414.5M to 532.1M.
What does shares (diluted) mean?
The weighted-average shares outstanding plus all potentially dilutive shares from stock options, RSUs, convertible securities, and warrants, using the treasury stock method.

Ask your AI about Arrowhead Research's shares (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude